A Comprehensive, Multimodality Quality of Life Study for Prostate Cancer Patients
试验速览
- 阶段
- 不适用
- 入组人数
- 1,051
- 试验地点
- 3
- 主要终点
- QOL: Expanded Prostate Cancer Index Composite (EPIC) Survey
研究概览
简要总结
The goal of this behavioral research study is to look at patients' quality of life after treatment or management for prostate cancer.
详细描述
Questionnaires:
You will complete 2 questionnaires that will ask you questions about your quality of life, urinary, bowel, sexual function, and any side effects that you may be having. You will be asked about any medications you may be taking and any other medical conditions you may have. The questionnaires will take about 20 minutes to complete. You may complete the questionnaires at the clinic, have them mailed to you (return postage will be included), or be asked the questions over the phone.
If you are on active surveillance (checking for prostate cancer by routine blood draws and biopsy, without active treatment), you will fill out the questionnaires on the same schedule as those receiving treatment that does not involve hormones.
If you are receiving therapy that does not involve hormones, you will complete the questionnaires before you receive treatment.
If you are receiving hormone therapy, you will complete the questionnaires before beginning the hormone therapy and then again within 3 weeks before starting radiation.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Primary treatment at MD Anderson for prostate cancer using: radical retropubic prostatectomy, robotic prostatectomy, photon external beam radiation, photon external beam radiation with hormone therapy, proton radiation, radioisotopic implant, cryotherapy, or active surveillance.
- •Neoadjuvant, concurrent and adjuvant androgen ablation in conjunction with photon external beam radiation is allowed if not greater than 6 months total duration. Hormone therapy will be given as an LHRH agonist with or without an antiandrogen.
- •Pathologic diagnosis of prostate adenocarcinoma
- •AJCC (VI) stage T1-T3b N0M0
- •Ability to read, write, and fill out the self-survey questionnaires
- •Patients may be simultaneously enrolled on other MD Anderson treatment or laboratory protocols. The EPIC Survey will be used for both this protocol and for protocol 2007-0209 such that patients enrolled on both protocols will complete only one document at each survey point. Simultaneous enrollment on other survey protocols will be handled in a similar manner.
排除标准
- •Histology other than adenocarcinoma
- •Stage T4, nodal or distant metastasis
- •Prior treatment for prostate cancer except for neoadjuvant, concurrent and adjuvant androgen deprivation of 6 months or less duration in patients treated with photon radiation. Hormone therapy in all other modalities is not allowed.
- •Chemotherapy or molecular targeting therapy as primary, neoadjuvant or adjuvant treatment
- •Treatment for another pelvic malignancy, to include surgery or radiation
- •Treatment for another malignancy with chemotherapy completed within one year or less of treatment for prostate cancer.
- •Inflammatory bowel disease (eg. Crohn's or Ulcerative Colitis)
- •Patients 18 years or younger.
结局指标
主要结局
QOL: Expanded Prostate Cancer Index Composite (EPIC) Survey
时间窗: Survey prior to beginning treatment, 3 months after completing treatment, 6 months after completing treatment, at 6 month intervals for the first 2 years post-treatment, and then yearly for 3 more years.
次要结局
未报告次要终点